Hepatitis C part 2: Treatment and prevention

In the second of two articles, Ray Poll discusses the treatment and prevention of hepatitis C, a global public health problem in the UK

[1]  R. Poll.  Hepatitis C part 1: Detection and assessment , 2012 .

[2]  C. Leen,et al.  UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients , 2012, Alimentary pharmacology & therapeutics.

[3]  H. Wedemeyer,et al.  Treating viral hepatitis C: efficacy, side effects, and complications , 2006, Gut.

[4]  P. Pockros,et al.  The management of side‐effects during therapy for hepatitis C , 2004, Alimentary pharmacology & therapeutics.

[5]  D. Dieterich,et al.  Hematologic disorders associated with hepatitis C virus infection and their management. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[7]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.